H. Shepard
Fondateur chez Enosi Life Sciences Corp.
Profil
H.
Michael Shepard was the founder of Receptor BioLogix, Inc. (founded in 2003) where he held the title of President & Chief Scientific Officer from 2003 to 2008.
He is also the founder of Enosi Life Sciences Corp.
(founded in 2018) where he currently holds the title of President, Director & Chief Scientific Officer.
In addition to his founding positions, Dr. Shepard has held former job positions.
He was an Independent Director at Nevis Brands, Inc. He worked at Genentech, Inc. as a Principal from 1980 to 1992.
From 2009 to 2017, he served as the Chief Scientific Officer & Vice President at Halozyme Therapeutics, Inc. He was also the President & Chief Scientific Officer at NewBiotics, Inc. from 1997 to 2008.
Prior to that, he held the position of Chief Scientific Officer & Vice President-Research at Canji, Inc. from 1992 to 1997.
Dr. Shepard's education includes a doctorate degree from Indiana University and an undergraduate degree from the University of California, Davis.
Postes actifs de H. Shepard
| Sociétés | Poste | Début |
|---|---|---|
Enosi Life Sciences Corp.
 Enosi Life Sciences Corp. BiotechnologyHealth Technology Enosi Life Sciences Corp. is a drug research and development company that focuses on providing therapeutics for autoimmune diseases and cancer. The private company is based in San Diego, CA, and was founded in 2018 by H. Michael Shepard and Marc Feldmann. Enosi Life Sciences combines their expertise with Dr. James N. Woody's medical, scientific, and management expertise to expand therapeutic options. The company was founded by Professor Sir Marc Feldmann and Dr. H. Michael Shepard, who are world-renowned scientists in the field of cancer and autoimmune diseases. Patrick W. Gray has been the CEO of the company since 2021. | Fondateur | 16/08/2018 |
Anciens postes connus de H. Shepard
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/02/2017 |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Fondateur | 02/01/2008 |
NewBiotics, Inc.
 NewBiotics, Inc. Pharmaceuticals: MajorHealth Technology NewBiotics, Inc. develops pharmaceutical drugs to treat cancer and infectious disease. It applies its Enzyme Catalyzed Therapeutic Activation technology to develop pharmaceuticals that transform drug resistance into therapeutic advantage. The company was founded by H. Michael Shepard and Geoffrey Myles Wahl in 1997 and is headquartered in San Diego, CA. | President | 01/01/2008 |
Canji, Inc.
 Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Directeur Technique/Scientifique/R&D | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Formation de H. Shepard
| Indiana University | Doctorate Degree |
| University of California, Davis | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
NewBiotics, Inc.
NewBiotics, Inc. Pharmaceuticals: MajorHealth Technology NewBiotics, Inc. develops pharmaceutical drugs to treat cancer and infectious disease. It applies its Enzyme Catalyzed Therapeutic Activation technology to develop pharmaceuticals that transform drug resistance into therapeutic advantage. The company was founded by H. Michael Shepard and Geoffrey Myles Wahl in 1997 and is headquartered in San Diego, CA. | Health Technology |
Receptor BioLogix, Inc.
Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
Canji, Inc.
Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Health Services |
Enosi Life Sciences Corp.
Enosi Life Sciences Corp. BiotechnologyHealth Technology Enosi Life Sciences Corp. is a drug research and development company that focuses on providing therapeutics for autoimmune diseases and cancer. The private company is based in San Diego, CA, and was founded in 2018 by H. Michael Shepard and Marc Feldmann. Enosi Life Sciences combines their expertise with Dr. James N. Woody's medical, scientific, and management expertise to expand therapeutic options. The company was founded by Professor Sir Marc Feldmann and Dr. H. Michael Shepard, who are world-renowned scientists in the field of cancer and autoimmune diseases. Patrick W. Gray has been the CEO of the company since 2021. | Health Technology |
